IMPORTANT WARNING:
Receiving an eculizumab injection product may increase the risk that you will develop a meningococcal infection (an infection that may affect the covering of the brain and spinal cord and/or may spread through the bloodstream) during your treatment or for some time afterward. Meningococcal infections may cause death in a short period of time. You will need to receive a meningococcal vaccine at least 2 weeks before you begin your treatment with an eculizumab injection product to decrease the risk that you will develop this type of infection. If you have received this vaccine in the past, you may need to receive a booster dose before you begin your treatment. If your doctor feels that you need to begin treatment with an eculizumab injection product right away, you will receive your meningococcal vaccine as soon as possible and take an antibiotic for as long as your doctor recommends.
Even if you receive the meningococcal vaccine, there is still a risk that you may develop meningococcal disease during or after your treatment with an eculizumab injection product. If you experience any of the following symptoms, call your doctor immediately or get emergency medical help: headache that comes along with nausea or vomiting, fever, a stiff neck, or a stiff back; fever ; rash and fever; fever with high heart rate; confusion; muscle aches and other flu-like symptoms; or if your eyes are sensitive to light.
Tell your doctor if you have fever or other signs of infection before you begin your treatment with an eculizumab injection product. Your doctor will not give you an eculizumab injection product if you already have a meningococcal infection.
Your doctor will give you a patient safety card with information about the risk of developing meningococcal disease during or for a period of time after your treatment. Carry this card with you at all times during your treatment and for 3 months after your treatment. Show the card to all healthcare providers who treat you so that they will know about your risk.
Programs called Soliris REMS or BKEMV REMS have been set up to decrease the risks of receiving an eculizumab injection product. You can only receive an eculizumab injection product from a doctor who has enrolled in one of these programs, has talked to you about the risks of meningococcal disease, has given you a patient safety card, and has made sure that you received a meningococcal vaccine.
Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with an eculizumab injection product and each time you receive an injection. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (https://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer's website to obtain the Medication Guide.
Talk to your doctor about the risks of receiving an eculizumab injection product.
IMPORTANT NOTICE:
Eculizumab injection and eculizumab-aeeb injection are biologic medications (medications made from living organisms). Biosimilar ustekinumab-aeeb injection is highly similar to eculizumab injection and work the same way as eculizumab injection in the body. Therefore, the term eculizumab injection products will be used to represent these medications in this discussion.